» Articles » PMID: 34059622

Antitumor Effect of Melaleuca Alternifolia Essential Oil and Its Main Component Terpinen-4-ol in Combination with Target Therapy in Melanoma Models

Overview
Date 2021 Jun 1
PMID 34059622
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Essential oils (EOs) have been recently emerging for their promising biological activities in preventing tumorigenesis or progression of different tumor histotypes, including melanoma. In this study, we investigated the antitumor activity of a panel of EOs in different tumor models. The ability of Melaleuca alternifolia (tea tree oil) and its main component, terpinen-4-ol, to sensitize the target therapy currently used for melanoma treatment was also assessed. Our results demonstrated that EOs differently affect the viability of human cancer cells and led us to select six EOs effective in melanoma and lung cancer cells, without toxic effects in human fibroblasts. When combined with dabrafenib and/or trametinib, Melaleuca alternifolia synergistically reduced the viability of melanoma cells by activating apoptosis. Through machine learning classification modeling, α-terpineol, tepinolene, and terpinen-4-ol, three components of Melaleuca alternifolia, were identified as the most likely relevant components responsible for the EO's antitumor effect. Among them, terpinen-4-ol was recognized as the Melaleuca alternifolia component responsible for its antitumor and proapoptotic activity. Overall, our study holds promise for further analysis of EOs as new anticancer agents and supports the rationale for their use to improve target therapy response in melanoma.

Citing Articles

Phytocompounds and Nanoformulations for Anticancer Therapy: A Review.

Bozzuto G, Calcabrini A, Colone M, Condello M, Dupuis M, Pellegrini E Molecules. 2024; 29(16).

PMID: 39202863 PMC: 11357218. DOI: 10.3390/molecules29163784.


Comparative Anti-Cancer and Anti-Inflammatory Activities of Essential Oils from the Bark and Flower of Rehd. et Wils.

Hao K, Hao Y, Zhang J, Xu X, Jiang J Foods. 2024; 13(13).

PMID: 38998580 PMC: 11241728. DOI: 10.3390/foods13132074.


Nanoemulsified Essential Oil of Leaves for Topical Application: In Vitro Photoprotective, Antioxidant and Anti-Melanoma Activities.

Sousa L, Santos M, Sampaio L, Faustino C, Guigueno M, Freitas K Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931388 PMC: 11206566. DOI: 10.3390/ph17060721.


Essential Oils Induce ROS-Mediated Autophagy and Apoptosis by Targeting SIRT1 in Colon Cancer Cells.

Islam A, Chang Y, Tsao N, Wang S, Chueh P Antioxidants (Basel). 2024; 13(3).

PMID: 38539819 PMC: 10967316. DOI: 10.3390/antiox13030284.


Essential Oils in Cervical Cancer: Narrative Review on Current Insights and Future Prospects.

Abd Rashid N, Mohamad Najib N, Abdul Jalil N, Teoh S Antioxidants (Basel). 2023; 12(12).

PMID: 38136228 PMC: 10740549. DOI: 10.3390/antiox12122109.


References
1.
Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

2.
Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick D . PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017; 550(7674):133-136. PMC: 5891348. DOI: 10.1038/nature24040. View

3.
Yuan R, Hou Y, Sun W, Yu J, Liu X, Niu Y . Natural products to prevent drug resistance in cancer chemotherapy: a review. Ann N Y Acad Sci. 2017; 1401(1):19-27. DOI: 10.1111/nyas.13387. View

4.
Flaherty L, Othus M, Atkins M, Tuthill R, Thompson J, Vetto J . Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group.... J Clin Oncol. 2014; 32(33):3771-8. PMC: 4226807. DOI: 10.1200/JCO.2013.53.1590. View

5.
Mattila K, Vihinen P, Ramadan S, Skytta T, Tiainen L, Vuoristo M . Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. Acta Oncol. 2019; 59(3):310-314. DOI: 10.1080/0284186X.2019.1670862. View